17-Mar-2026
No press releases found.
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
XBI Bullish Call Spread is Undervalued at $4.25
Market Chameleon (Tue, 9-Apr 7:04 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of March 17, 2026, XBI stock price climbed to $124.19 with 5,526,025 million shares trading.
XBI has a beta of 0.96, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.40 to the broad based SPY ETF.
XBI has a market cap of $7.65 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $132.09 and as low as $63.80.
XBI has outperformed the market in the last year with a price return of +41.2% while the SPY ETF gained +19.6%. XBI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +3.0% and +0.6%, respectively, while the SPY returned +0.2% and -1.4%, respectively.
XBI support price is $121.74 and resistance is $126.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.